Newsfeeds - Spark Newswire

4 minute read

Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday’s Mid-Day Session

Today, 4:54 PM

Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.

AKTX

3 minute read

Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

Today, 4:54 PM

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck‘s (NYSE:MRK) lead asset MK-2060…

AMGN

1 minute read

News

Immatics Biotechnologies Granted U.S. Patent #11,414,473 Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers

By Charles Gross

Today, 4:54 PM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5460&f=G&l=50&d=PTXT&p=110&S1=20220816&OS=20220816&RS=20220816

IMTX

3 minute read

Why Is CarLotz Higher By More Than 30%: Here Are 28 Stocks Moving Premarket

By Lisa Levin

Today, 4:54 PM

Gainers ObsEva SA (NASDAQ: OBSV) shares rose 33.8% to $0.4080 in pre-market trading. ObsEva recently announced a $31 million debt retirement and $11 million debt refinancing.

ABCL

5 minute read

Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday

By Lisa Levin

Today, 4:54 PM

Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue forecast.

AEZS

2 minute read

12 Health Care Stocks Moving In Tuesday’s Intraday Session

By Benzinga Insights

Today, 4:54 PM

APLS

1 minute read

News

Immatics Biotechnologies Granted U.S. Patent #11,390,660 Uterine cancer treatments

By Charles Gross

Today, 4:54 PM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5468&f=G&l=50&d=PTXT&p=110&S1=20220719&OS=20220719&RS=20220719

IMTX

1 minute read

News

Immatics Biotechnologies Granted U.S. Patent #11,352,401 Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers

By Charles Gross

Today, 4:54 PM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5441&f=G&l=50&d=PTXT&p=109&S1=20220607&OS=20220607&RS=20220607

IMTX

1 minute read

SVB Leerink Maintains Outperform on Immatics, Raises Price Target to $26

By Benzinga Newsdesk

Today, 4:54 PM

SVB Leerink analyst Jonathan Chang maintains Immatics (NASDAQ:IMTX) with a Outperform and raises the price target from $25 to $26.

IMTX

1 minute read

Immatics Q1 Sales $114.20M Up From $8.70M YoY

By Benzinga Newsdesk

Today, 4:54 PM

Immatics (NASDAQ:IMTX) reported $114.20 million in sales this quarter. This is a 1.21K percent increase over sales of $8.70 million the same period last year.

IMTX